Entero Healthcare Solutions Ltd
Incorporated in 2018, Entero Healthcare Solutions Limited is a distributor of healthcare products in India[1]
- Market Cap ₹ 6,243 Cr.
- Current Price ₹ 1,435
- High / Low ₹ 1,516 / 970
- Stock P/E 110
- Book Value ₹ 374
- Dividend Yield 0.00 %
- ROCE 3.99 %
- ROE 4.97 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Stock is trading at 3.84 times its book value
- Earnings include an other income of Rs.107 Cr.
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|
105 | 137 | 178 | 318 | 379 | |
137 | 191 | 222 | 353 | 408 | |
Operating Profit | -32 | -54 | -44 | -34 | -29 |
OPM % | -30% | -39% | -25% | -11% | -8% |
23 | 27 | 53 | 90 | 107 | |
Interest | 2 | 5 | 11 | 22 | 18 |
Depreciation | 7 | 9 | 10 | 9 | 9 |
Profit before tax | -18 | -41 | -12 | 24 | 52 |
Tax % | 0% | 0% | 0% | -58% | |
-18 | -41 | -12 | 38 | 57 | |
EPS in Rs | -1,811.38 | -106.10 | -30.31 | 8.84 | 12.63 |
Dividend Payout % | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 45% |
TTM: | 79% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 60% |
TTM: | 408% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 5% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|
Equity Capital | 0 | 4 | 4 | 43 |
Reserves | -31 | -72 | -84 | 1,583 |
540 | 674 | 775 | 18 | |
23 | 47 | 68 | 125 | |
Total Liabilities | 533 | 654 | 764 | 1,769 |
50 | 51 | 41 | 34 | |
CWIP | 2 | 0 | 0 | 0 |
Investments | 39 | 39 | 41 | 41 |
442 | 563 | 682 | 1,694 | |
Total Assets | 533 | 654 | 764 | 1,769 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|
-68 | -45 | -57 | -76 | |
-7 | -69 | -58 | -763 | |
76 | 127 | 91 | 926 | |
Net Cash Flow | 0 | 14 | -24 | 87 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|
Debtor Days | 107 | 139 | 153 | 130 |
Inventory Days | 177 | 103 | 68 | 65 |
Days Payable | 48 | 99 | 132 | 88 |
Cash Conversion Cycle | 236 | 143 | 89 | 107 |
Working Capital Days | 1,210 | 1,123 | 1,086 | 855 |
ROCE % | -6% | -0% | 4% |
Documents
Announcements
- Closure of Trading Window 1d
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 2d
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
18 Sep - Schedule of meetings with institutional investors.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
17 Sep - Of Schedule of Analyst / Institutional Investor meetings under the SEBI (LODR), Regulations 2015 to be held on 20th September, 2024
-
Announcement under Regulation 30 (LODR)-Credit Rating
10 Sep - India Ratings upgrades Entero Healthcare to 'IND A-'/Stable.
Concalls
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT REC
-
May 2024TranscriptNotesPPT
-
Mar 2024Transcript PPT
Leading Healthcare Product Disributor[1] The company is among the top three healthcare distributors in India in terms of revenue. Further, it achieved the fastest scale-up of operations among healthcare product distributors in India between FY19 - FY22.